| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Review Articles |
Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts
Requests for reprints: Bruce E. Johnson, Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. Phone: 617-632-4790; Fax: 617-632-5786; E-mail: BEJohnson{at}Partners.org.
A year has passed since mutations of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) were discovered in patients with non–small cell lung cancer (NSCLC) who had dramatic clinical responses to treatment with gefitinib. Additional laboratory and clinical studies have provided further insight into the biological impact of EGFR mutations in cell culture experiments and in patients with NSCLC. In vitro characterizations of NSCLC cell lines and host cell lines transfected with these mutant and wild-type EGFR show that most cell lines with mutated EGFR are growth-inhibited by 10- to 100-fold lower concentrations of gefitinib and erlotinib compared with wild-type EGFR. NSCLC lines with mutations of the EGFR treated with concentrations of gefitinib and erlotinib that are achievable in the plasma undergo apoptosis rather than growth arrest. Retrospective studies of patients with NSCLC-treated gefitinib have reported a close association between EGFR mutations, increased chance of clinical response and longer survival. This review will provide information on the impact of EGFR mutations on gefitinib and erlotinib treatment by in vitro experiments, the outcome of NSCLC patients with these mutations when treated with gefitinib and erlotinib, and the subsets of patients with NSCLC in whom these mutations arise.
This article has been cited by other articles:
|
|
 |
|
  H. Li, X. Xing, G. Ding, Q. Li, C. Wang, L. Xie, R. Zeng, and Y. Li SysPTM: A Systematic Resource for Proteomic Research on Post-translational Modifications Mol. Cell. Proteomics, August 1, 2009; 8(8): 1839 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sartori, A. Cavazza, A. Sgambato, A. Marchioni, F. Barbieri, L. Longo, M. Bavieri, B. Murer, E. Meschiari, S. Tamberi, et al. EGFR and K-ras Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors Am J Clin Pathol, April 1, 2009; 131(4): 478 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zannetti, F. Iommelli, R. Fonti, A. Papaccioli, J. Sommella, A. Lettieri, G. Pirozzi, R. Bianco, G. Tortora, M. Salvatore, et al. Gefitinib Induction of In vivo Detectable Signals by Bcl-2/Bcl-xL Modulation of Inositol Trisphosphate Receptor Type 3 Clin. Cancer Res., August 15, 2008; 14(16): 5209 - 5219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, W. K. K. Wu, L. Yu, Z. J. Li, J. J. Y. Sung, S. T. Zhang, and C. H. Cho Epidermal Growth Factor-Induced Esophageal Cancer Cell Proliferation Requires Transactivation of {beta}-Adrenoceptors J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 69 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Benedetti, P. Perego, G. Luca Beretta, E. Corna, S. Tinelli, S. C. Righetti, R. Leone, P. Apostoli, C. Lanzi, and F. Zunino Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds Mol. Cancer Ther., March 1, 2008; 7(3): 679 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Yun, K. E. Mengwasser, A. V. Toms, M. S. Woo, H. Greulich, K.-K. Wong, M. Meyerson, and M. J. Eck The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP PNAS, February 12, 2008; 105(6): 2070 - 2075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Deng, T. Shimamura, S. Perera, N. E. Carlson, D. Cai, G. I. Shapiro, K.-K. Wong, and A. Letai Proapoptotic BH3-Only BCL-2 Family Protein BIM Connects Death Signaling from Epidermal Growth Factor Receptor Inhibition to the Mitochondrion Cancer Res., December 15, 2007; 67(24): 11867 - 11875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pandey, S. M. Umphress, Y. Kang, J. Angdisen, A. Naumova, K. L. Mercer, T. Jacks, and S. B. Jakowlew Modulation of tumor induction and progression of oncogenic K-ras-positive tumors in the presence of TGF- 1 haploinsufficiency Carcinogenesis, December 1, 2007; 28(12): 2589 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sutterluty, C.-E. Mayer, U. Setinek, J. Attems, S. Ovtcharov, M. Mikula, W. Mikulits, M. Micksche, and W. Berger Down-Regulation of Sprouty2 in Non-Small Cell Lung Cancer Contributes to Tumor Malignancy via Extracellular Signal-Regulated Kinase Pathway-Dependent and -Independent Mechanisms Mol. Cancer Res., May 1, 2007; 5(5): 509 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Steiner, C. Joynes, R. Bassi, S. Wang, J. R. Tonra, Y. R. Hadari, and D. J. Hicklin Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor Clin. Cancer Res., March 1, 2007; 13(5): 1540 - 1551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schaefer, L. Shao, K. Totpal, and R. W. Akita Erlotinib Directly Inhibits HER2 Kinase Activation and Downstream Signaling Events in Intact Cells Lacking Epidermal Growth Factor Receptor Expression Cancer Res., February 1, 2007; 67(3): 1228 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-L. Chang, C.-T. Wu, S.-C. Lin, C.-F. Hsiao, Y.-S. Jou, and Y.-C. Lee Clonality and Prognostic Implications of p53 and Epidermal Growth Factor Receptor Somatic Aberrations in Multiple Primary Lung Cancers Clin. Cancer Res., January 1, 2007; 13(1): 52 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Clackson Translational Research in Academia and Industry Experimental Biology and Medicine, December 1, 2006; 231(11): 1685 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Das, M. Sato, M. D. Story, M. Peyton, R. Graves, S. Redpath, L. Girard, A. F. Gazdar, J. W. Shay, J. D. Minna, et al. Non-Small Cell Lung Cancers with Kinase Domain Mutations in the Epidermal Growth Factor Receptor Are Sensitive to Ionizing Radiation Cancer Res., October 1, 2006; 66(19): 9601 - 9608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Krueger and S. Srivastava Posttranslational Protein Modifications: Current Implications for Cancer Detection, Prevention, and Therapeutics Mol. Cell. Proteomics, October 1, 2006; 5(10): 1799 - 1810. [Full Text] [PDF]
|
|
|
|
|
|
T. Kosaka, Y. Yatabe, H. Endoh, K. Yoshida, T. Hida, M. Tsuboi, H. Tada, H. Kuwano, and T. Mitsudomi Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res., October 1, 2006; 12(19): 5764 - 5769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Carey, A. J. Garton, M. S. Romero, J. Kahler, S. Thomson, S. Ross, F. Park, J. D. Haley, N. Gibson, and M. X. Sliwkowski Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib Cancer Res., August 15, 2006; 66(16): 8163 - 8171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Dasari, M. Gallup, H. Lemjabbar, I. Maltseva, and N. McNamara Epithelial-Mesenchymal Transition in Lung Cancer: Is Tobacco the "Smoking Gun"? Am. J. Respir. Cell Mol. Biol., July 1, 2006; 35(1): 3 - 9. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
